Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer Female
Interventions: DRUG: Ribociclib 200Mg Oral Tablet
Sponsor: West German Study Group
Collaborators: Novartis|Genomic Health®, Inc.